To investigote the effect on participation in colorectal cancer screening of testing for blood products in faeces using technologies that remove dietary restrictions (i.e. immunochemical tests) and simplify faecal sampling (i.e. tests that use brush sampling).
INTRODUCTION
T h e type of faecal occult blood test (FOBT) used in randomised controlled trials of screening.':" for col?rectal cancer was developed four decades ago."? This, the Hemoccult® test, uses simple chemical means to detect occult blood in the stool, specifically, a method using guaiac which reacts to the peroxidase activity of haem (and other peroxidases in the stool). Such a method presents significant problems with false-positive and false-negative results brought about by certain dietary components, vitamin supplements and drugs. R -11 The most often studied guaiacbased method, Hernoccult, has also traditionally used a wooden spatula for sampling the stool.'? Since the advent of the Hemoccult test, new methods for detecting occult blood in stool have become available." which differ in two particular aspects.
The first is that the target molecule, or analyte, has been changed from haem to globin.P'!" This confers several advantages. This different class of test also uses an antibody for the detection of occult blood. The test result is visualised using a range of technological means, including tagged red cell agglutination, latex agglutination and immunocapture technologies in which reagents diffuse across a membrane. These faecal immunochemical tests (FITs) for haemoglobin are analytically specific for haemoglobin 11.1' and are unaffected by diet or drugs.'>" They are selective for occult bleeding of colorectal origin and do not detect occult gastric www.jmedscreen.com bleeding. I R . 19 They also provide improved sensitivity for colorectal cancer without major compromise of specificity;" when compared with guaiac tests such as the various versions of Hemoccult. Efforts to improve the sensitivity of guaiac tests have compromised specificity, especially if diet and drug restrictions have not been followed. 9.16.17.21.22 Unfortunately, requiring such restrictions creates a significant barrier to participatiorr'":" and in a cohort of motivated volunteers reduced participation by almost 13 %. 26 Additionally, more false-positives occur if participants do not follow the recommendations."
The second differing aspect is the method of stool sampling. The spatula sampling method used for most guaiac tests is not well favoured" and, ideally, requires a person to sample the stool while avoiding its immersion in toilet bowl water." Some FITs have incorporated more innovative stool-sampling methods that would seem to simplify the process, either by requiring only brief contact with nonimmersed stool (e.g. probe or spoon) or by using a brush to sample the stool while it is imrnersed.F'??
Inconvenience of the screening test and aversion to manipulating faeces are two of the key barriers to participation in screening.t'r" Thus, changes to both the test analyte and the sampling method would seem likely to confer behavioural advantages at the population level, in that they could lead to better participation rates in screening based on detection of blood products in faeces. A better impact on population mortality ought to follow from a higher participation rate, with likely benefits in cost-effectiveness as well." However, will the perceived behavioural advantages of the FITs and their various sampling methods translate into real benefit in terms of population participation? To answer this question for a typical Western-style screening population, it is important to identify whether benefit is attributable to each perceived aspect of improvement and whether the benefits are additive.
Thus, we measured participation rates in three cohorts each receiving a different technology test, by randomly selecting invitees from an urban population using the electoral roll as the source of invitees. The tests used were: Hemoccult SENSA (a guaiac FOBT using spatula sampling of stools, with recommendation for a low-peroxidase diet and avoidance of interfering drugs), Plex Sure" OBT (a FIT using spatula sampling of stools) and Insure" (a brush-sampling FIT). This design enabled us to measure the separate and combined impact of simplified sampling and removal of dietary and drug restrictions.
MATERIALS AND METHODS

Study population
A pool of 4000 potential invitees aged 50-69 years was randomly selected from the electoral roll of the Australian Electoral Commission, by the Commission, from those in urban postcodes 5043-4,5047-51,5157-9,5161 and 5162. These postcodes corresponded to the major catchment area for the Repatriation General Hospital Daw Park and represented a broad range of socio-economic index for areas (SEIFA), from 915 to 1127; the median for urban Adelaide is 998.42 Exposure of this population to screening was low by US standards and prior participation in screening had been less than 20%. 43 To select invitees, the 4000 were assigned a random number by SC using the random number function of the software program Excel (Microsoft, USA). These were ranked in ascending order, with the corresponding individuals' names concealed. The first 606 were allocated to the Hemoccult group, the second 606 to the FlexSure OBT group and the third 606 to the InSure group. There were no exclusions.
Randomised controlled trials and our own experience indicated that participation rates in FOBT-based community screening programs varied between 30_70%.1-3. 26 We considered a 10% difference between participation rates to be meaningful. With a sample size in each cohort of 606, a 0.05 two-sided significance level X 2 test had 95% power to detect a difference in proportions characterised by a variance of proportions of 0.00172 and an average proportion of 0.370, Le. the minimum and maximum participation rates were expected to range from 32% to 42% (calculated using nQuery Adviser software, release 4.0, programmed by JD Elashoff, Statistical Solutions, Cork, Ireland).
Offer of screening test
Identical invitations-to-screen were used for each cohort, although the type of test offered could not, by the nature of the study, be concealed. The invitation was sent from a central screening service (Bowel Health Service, Repatriation General Hospital, Adelaide, Australia) without any publicity. The letter of invitation was accompanied by: (1) an information sheet on screening for colorectal cancer; doctor for follow-up and a section for provision of consent. Invitees were asked to complete the screening test according to manufacturer's instructions and to return samples and questionnaires by mail to the Bowel Health Service. There was no cost to the invitee.
Reminders were sent by mail six weeks after the initial mail-out if a completed collection card had not been received. Offers were made between April 2001 and August 2001.
Faecal occult blood tests
Hemoccult SENSA (Beckman Coulter Inc., Palo Alto CA, USA) is a guaiac FOBT that reacts to the peroxidase activity of haem.>":" Invitees were asked to use the manufacturer's wooden spatula to sample each of three stools (two windows from each), keeping the stool clear of toilet bowl water using a paper "raft" (provided) so as to reduce leaching of haem from the surface.7.22.28 The restrictions applicable to testing with a guaiac test, and ideal for control of specificity,22.28 were given as follows:
"At least 72 hours before and during sample collection, avoid eating:
-red meat (beef and lamb), including processed meats and liver uncooked or lightly cooked turnips, horseradish, broccoli, radishes and cauliflower (permitted if well cooked) -rockmelon or cantaloupe (watermelon permitted) -vitamin C supplements Do not take aspirin or nonsteroidal anti-inflamatory drugs for 7 days prior to sampling stools."
FlexSure OBT (Beckman Coulter Inc.) is a FIT test with analytical characteristics comparable with those of Immudia-Hem Sp (Fujirebio Inc., Tokyo, Japan) and the now discontinued HemeSelect (Beckman Coulter Inc.)44 (see also product insert). Invitees were asked to sample each of three stools (one card per stool) using a spatula similar to that for Hemoccult, keeping the stool clear of toilet bowl water. No dietary or drug restrictions were recommended.
InSure (Bnterix Inc., Portland ME, USA) is a new FIT test approved by the US Foods and Drugs Authority. Like FlexSure OBT, it uses membrane technology and immunolabelled colloidal gold to detect haemoglobin, and diet and drug restrictions are therefore unnecessary. It uses a different approach to sample the stool, and requires sampling from two rather than three stools. The invitee is asked to sample the stool by briefly brushing the surface of the stool while immersed in toilet bowl water. The brush retains an approximately constant volume that is transferred by dabbing it onto one of two windows of the sample card. The second stool is separately sampled onto the other window.
Development and follow-up
The date of return of sample cards was recorded. Tests were developed by the authors (SC, BC) according to manufacturers' directions, following instructions from the manufacturers and proficiency testing. Positive controls were included for each test batch. Sample cards were stored and developed within the limits specified for each test. Hemoccult cards were not developed within 72 hours of sampling to minimise interference by plant peroxidases.v'r" If any stool sample returned a positive reaction, the overall result for that person was considered positive. Participants were advised of the results (positive or negative) within five days of receipt of www.jmedscreen.com Participation in colorectal concer screening samples. In the case of a positive result, the participant and his/her primary care practitioner were notified and colonoscopic follow-up arranged. Diagnosis was ascertained from colonoscopy and pathology reports, with the participant's consent; colonoscopists were blinded to the test type.
Outcome measures and analyses
Primary aim 1: To determine the impact of removal of diet and drug restrictions on population participation (i.e. rates and time to return specimens), in a screening program for colorectal cancer based on detection of blood products in faeces, determined by comparing Hemoccult SENSA with FlexSure GBT cohorts. Participation was defined as the return of completed stool collection devices within 12 weeks of mailing the initial kit. Participation rates were compared between cohorts by X 2 analysis." Analyses were conducted on an "intention-to-treat" basis, with groups blinded in the analyses. There were no exclusions; for instance, even if an invitation was returned because the person no longer resided at the address, they remained in the analysis.
Primary aim 2: To determine the impact on population participation of simplified sampling of stools using a brush, determined by comparing FlexSure GBT with InSure cohorts. Definitions and analyses were as for aim I.
Primary aim 3: To determine the combined impact of simplified sampling of stools and removal of food and drug restrictions on population participation, determined by comparing Hemoccult SENSA with Insure cohorts. Definitions and analyses were as for aim I.
Secondary aim: To determine whether the demographic variables gender, age and socia-economic status are confounding factors for participation in screening. A measure of socia-economic status was derived from the postcodes of those invited using the "Index of Disadvantage" made available by the Australian Bureau of Statistics and based on data from the 1996 national census." Univariate analyses were made by X 2 analysis. Multivariate analyses were conducted by generalised linear modelling (GLM; Intercooled Stata software, release 5; Stata, College Station, Texas, USA) to obtain a relative risk (RR) estimate of the key variable, followed by stepwise addition of gender, age and socioeconomic status variables to determine whether there was a greater than 10% change in RR estimates. The dependent variables used were the behavioural characteristics of the test offered, i.e. restrictions needed and stool-sampling method.
Ethical 
RESULTS
Characteristics of screening test cohorts
A comparison of the demographic characteristics of the cohorts is shown in Table I . The cohorts were well matched for age distribution and gender but not for socia-economic status, with a greater proportion in the FlexSure GBT cohort being economically advantaged than in the others (p=0.047).
Participation rates and test type
Participation rates at 12 weeks differed significantly between cohorts (p<O.OO I, X 2"37.1). Rates relative to age, gender and socia-economic status are shown in Table 2 .
Effect of elimination of diet and drug restrictions A significantly higher participation rate was observed in those offered FlexSure GBT versus those offered Hemoccult SENSA (30.5% and 23.4%. respectively, p=0.007, X 2 " 7 .39 ). By GLM, RR for participation was 1.276 (95% confidence intervals [CI] 1.059-1.537, p=O.OIO) Effect of simplified stool sampling A significantly higher participation rate was observed in those offered InSure versus those offered FlexSure GBT (39.6% and 30.5%, respectively, p=0.002, x 2 " 1O.6 ). By GLM, RR for participation was 1.297 (95% CI 1.111-1.515, p=O.OOI).
Effect of combining simplified stool sampling with elimination of diet and drug restrictions
A significantly higher participation rate was observed in those offered InSure versus those offered Hemoccult SENSA (39.6% and 23.4%, respectively, p<O.OOL x 2 = 36.0 ). By GLM, RR for participation was 1.655 (95% CI 1.393-1.967, p<O.OOI).
Time taken to return sample cards
The week-by-week return of stool sample cards is shown for each test in Figure I ; these data suggest that the differences in rate of return between tests occurred largely in the first three weeks. Comparison of the rates of return between the first six weeks and the second six weeks (after the reminder 'The difference was solely due to those in the FlexSure OBT cohort having a higher praportion of invitees above the median measure for Adelaide. SEIFA (socioeconomic index for areas) is a measure of socio-economic status shown according to whether the subject was above or below the median for the Adelaide metropolitan area (see methods). FOBT, faecal occult blood test. letter) is shown in Table 3 ; this analysis confirms that all of the difference in rates of return between tests occurred during the first six weeks. For the Hemoccult cohort, the rate of return was the same in each of the two six-week periods, whereas it was significantly higher in the first six weeks for the InSure and FlexSure OBT cohorts.
Assaciatians between demographic variables and participation
Univariate analyses (see Table 2 ) suggested a nonsignificant trend to better participation from women and those aged 60-69 years, and a statistically significant trend towards higher participation for those residing in the higher socioeconomic area (p=0.047). However, the GLM analysis for each comparison demonstrated that none of these three variables appeared to confound the relationship between participation and type of test, and hence no adjustment was required. Table 4 shows the relative risk for each comparison obtained by GLM. Positivity rates for each test were: InSure, 17/249 (6.8%); FlexSure OBT, 91I95 (4.6%) and Hemoccult SENSA, 9/157 (5.7%). These were not statistically significantly different. Of the 35 with positives tests, all received colonoscopic followup. Seventeen had adenomas (all 4 mm or larger), giving a PPY of 48.6%. Ten had non-neoplastic pathology in the colon or rectum (one had Crohn's disease) and the rest were normal. If advanced neoplasia is defined as adenomas of 2':10 mm, villous change, high-grade dysplasia or greater than two adenomas of any size, then the PPY for advanced neoplasia was 12/35 (34.3%). Numbers were too small for comparisons between tests.
Table 4
Comparison of participation rates based on generalised linear models"
Positive test results
• Age, gender and socio-economic stotus were not confounding voriables and therefore were not included in the above madels.
RR, relative risk; CI, canfidence intervals.
DISCUSSION
The design of this study enabled us to examine, for the first time, whether the perceived behavioural advantages of the FITs and the simplified stool-sampling option translate into real benefit as determined by population participation. Barriers to participation fall into several categories, including: inconvenience of the process, aversion to manipulating o Hemoccult OFI 5 4 5 6 7 8 9 10 11 12
Weeks token to return test faeces, lack of perceived benefit, fear of diagnosis, cost and personal Invulnerability.">" By studying an urban population in which screening is relatively infrequent, we have been able to show that benefit is derived by addressing the first two of these -by changing test analyte from haem to globin and changing sampling method from spatula sampling of three stools to brush sampling of two stools. Both benefits are incorporated in the brush-sampling FIT technology. The magnitude of the mortality reduction in population screening is dependent on several key issues." In the context of population screening, the willingness of individuals to perform the screening test (participation) assumes equal importance with the sensitivity of the test, for without participation no detection is possible,"-" The randornised controlled trials of population screening for colorectal cancer using guaiac-based occult blood tests have shown a reduction in mortality (on an intention-to-screen basis) of 15-18% with biennial screening and participation rates of a little over 50%2.3 and a reduction in mortality of 33% by annual screening with participation rates of around 80%.1-4 These trial-based participation rates (aided by publicity and perhaps intensive recruiting) do not necessarily reflect participation rates in a typical urban setting that is relatively naive to the value and practice of screening -we have studied such a setting.
The inconvenience of the screening process, e.g. the need for dietary and drug restrictions, is one factor that might act as a barrier to participation." With guaiac tests, high intake of vitamin C can cause false-negatives." Ingestion of nonsteroidal anti-inflammatory drugs (NSAIDs) may produce gastrointestinal bleeding and hence a false-positive for neoplasia;" Furthermore, plant peroxidases and haem from dietary blood and myoglobin (such as in red meats)? will cause false-positives. Restriction of intake of these substances improves test accuracy, especially for the more sensitive guaiac tests. 2l · 22 A recent review has suggested that such restrictions are not necessary for the less sensitive guaiac tests." but the more sensitive tests such as Hemoccult SENSA, which can return unpredictably high positivity rates in screening populations;" do require such restrictions if one wishes to control specificity and hence the cost of follow-up colonoscopies.
Several previous studies have addressed the effect of dietary and drug restrictions on participation, but these studies have shown varying results and have been subject to several possible biases." We have previously shown that a restrictive diet reduces participation by 13% to 54%, down from 67%, in motivated volunteers in a setting where red meat consumption is relatively high." In a true population study without any selection bias or publicity, we now show that removal of these restrictions significantly improves participation (increase in RR of 28%) and so reduces the inconvenience barrier.
Little is known about the impact of aversion to manipulating faeces on participation at the population level, except that people quote it as a reason for not participating." The thought of having to sample stool might mean that no attempt at all is made to take a sample. On the other hand, the experience of sampling could reinforce any distaste. Simpler sampling, either in terms of sampling fewer stools or doing so with less manipulation, would seem to address inconvenience as well as faecal aversion. Brushing the stool surface in the toilet bowl water would seem simpler than sampling with a spatula from stool kept clear of the toilet bowl water. In addition, InSure requires just two rather than three faecal samples; this further simplifies sampling. Our www.jmedscreen.com 121 results demonstrate that simplification of the sampling process also improves participation (increase in RR of 30%).
It is noteworthy that combining removal of restrictions and simplification of sampling further enhances participation (increase in RR of 66%), indicating that both technological advances offered by the brush-sampling FIT technology are worthwhile in practice.
Both strategies to enhance participation had their impact within the first six weeks, and mostly within the first three weeks (see Figure 1 ). While the six-week reminder letter generated a worthwhile additional response, there were no differences in participation between the different test cohorts after that time. Perhaps minimisation of these barriers tends to be more effective in those who react impulsively to health maintenance strategies.
Univariate analysis indicated a trend to better participation in women, but this was not statistically significant or confirmed in the multivariate analysis. In earlier studies, when screening by a FIT, we have shown a similar trend.":" In general, studies of colorectal cancer screening have not shown a consistent relationship between participation and gender. Other data suggest that women are more compliant with health maintenance behaviour, including participation in colorectal cancer screening in Australia." Yet men may be more likely to participate in screening by flexible sigmoidoscopy.V:" The interaction between gender and participation needs more detailed exploration to determine whether we need to consider gender-specific approaches.
Univariate analysis also indicated a trend to better participation in those aged 60-69 years than in those in the previous decade but again, this was not statistically significant. Other studies have suggested better population participation rates in the older age group." Some studies have shown that socio-economic status does impact on participation or on intention to participate in screening for colorectal cancer, 27.32 .34 yet our analysis demonstrated that socioeconomic status was not a confounding factor. The reasons why these associations were not seen in this study remain conjecture for now, but might reflect complex cultural factors that vary between populations.
CONCLUSION
Inconvenience of dietary and drug restrictions and aversion to sampling faeces are two significant barriers to participation in screening for colorectal cancer. The newer faecal haemoglobin test technologies provide the means, however, to overcome both these barriers. The best improvement in participation is achieved using a brush-sampling faecal immunochemical test for haemoglobin, as it addresses both barriers. Furthermore, we have shown that these improvements are not influenced by gender, age or socio-economic status, variables known to influence screening in other settings. This new technology should contribute to better detection of neoplasia at the population level by improving population participation rates.
